中华放射肿瘤学杂志
Thursday, Apr. 3, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2020, Vol. 29 Issue (7): 523-528    DOI: 10.3760/cma.j.cn113030-20190623-00239
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical outcome of radiotherapy for primary tumors in stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion
Wei Tianyu, Ma Zhu, Chen Xiaxia, Li Xiaoyang, Ouyang Weiwei, Su Shengfa, Li Qingsong, Geng Yichao, Yang Wengang, Hu Yinxiang, Li Huiqin, Lu Bing
Department of Oncology, Guizhou Medical University/Department of Oncology, Affiliated Hospital of Guizhou Medical University/Guizhou Cancer Hospital, Guiyang 550004, China
Download: PDF (753 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To retrospectively analyze the clinical efficacy and safety of three-dimensional radiotherapy for the primary tumors in patients with stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion (MPE-NSCLC). Methods A total of 198 patients who were initially pathologically diagnosed with MPE-NSCLC from January 2007 to April 2018 were enrolled and divided into the untreated group (n=45), drug group (n=57) and radiotherapy group (n=96), respectively. The short-term efficacy, overall survival (OS) and adverse events in the drug and radiotherapy groups were analyzed. The OS rate was analyzed by Kaplan-Meier method and log-rank test. Clinical prognosis was evaluated by multivariate Cox's regression model. Results In the radiotherapy group, the objective response rate and non-response rate was 54% and 46%, significantly better than 25% and 75% in the drug group (P=0.007). In the radiotherapy group, the 1-, 2-, 3-, 5-year OS and median survival was 47%, 18%, 6%, 1% and 12 months, remarkably higher than 15%, 3%, 2%, 0% and 5 months in the drug group, respectively (all P<0.001). Multivariate Cox's regression analysis showed that radiotherapy for the primary tumors was an independent prognostic factor to prolong the OS (P<0.001). Radiotherapy at a dose of ≥63Gy and 4-6 cycles of chemotherapy tended to prolong the OS (P=0.063 and 0.071). The OS of patients with EGFR mutation receiving radiotherapy combined with molecular target therapy was significantly better than that of those with unknown EGFR status treated with radiotherapy and chemotherapy (P=0.007). Addition of radiotherapy for the primary tumors did not significantly increase the incidence of adverse events (P>0.05). Conclusion Addition of three-dimensional radiotherapy for the primary tumors in MPE-NSCLC patients may prolong the OS and yield tolerable adverse events.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Wei Tianyu
Ma Zhu
Chen Xiaxia
Li Xiaoyang
Ouyang Weiwei
Su Shengfa
Li Qingsong
Geng Yichao
Yang Wengang
Hu Yinxiang
Li Huiqin
Lu Bing
Key wordsLung neoplasm/chemotherapy      Lung neoplasm/three-dimensional radiotherapy      Malignant pleural effusion      Prognosis     
Received: 23 June 2019     
Fund:Guizhou Science and Technology Planning Project (Qian Sci Co-supports[2019]2795)
Corresponding Authors: Lu Bing, Email:lbgymaaaa@163.com   
Cite this article:   
Wei Tianyu,Ma Zhu,Chen Xiaxia et al. Clinical outcome of radiotherapy for primary tumors in stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 523-528.
Wei Tianyu,Ma Zhu,Chen Xiaxia et al. Clinical outcome of radiotherapy for primary tumors in stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 523-528.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190623-00239     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I7/523
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn